What is it about?
This review aims to investigate the role of SCFAs as key epigenetic metabolites that mediate VLCKD–gut microbiota relationships in children, and their therapeutic potential in IBD.
Featured Image
Why is it important?
It is hypothesized that the VLCKD influences SCFA-producing bacteria and reduces gut inflammation in IBD. However, the mechanism by which SCFAs could mediate VLCKD–gut microbiota relationships and the therapeutic implications for reducing IBD are largely unknown.
Perspectives
Given that the VLCKD influences the gut SCFA-producing bacteria in children, it may have a potential role in inducing remission and mitigating inflammation in IBD, but further studies are needed to evaluate whether changes in the gut microbiota-producing SCFAs are associated with specific inflammation markers before, during, and after treatment with the VLCKD. Further studies of the VLCKD to assess its safety for the treatment in paediatric IBD patients are also needed.
Dr Naser Alsharairi
Griffith University
Read the Original
This page is a summary of: The Therapeutic Role of Short-Chain Fatty Acids Mediated Very Low-Calorie Ketogenic Diet–Gut Microbiota Relationships in Paediatric Inflammatory Bowel Diseases, Nutrients, October 2022, MDPI AG,
DOI: 10.3390/nu14194113.
You can read the full text:
Contributors
The following have contributed to this page
